Skip to main content
SpringerLink
Log in

Fortgeschrittene Hodentumoren: Therapie

  • Living reference work entry
  • First Online:
Uroonkologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 32 Accesses

Zusammenfassung

Die Tumorstadien IIC und III klassifizieren die fortgeschrittenen Hodentumoren. Ihre Therapie erfolgt stadiengerecht nach der IGCCCG Klassifikation, die drei Prognosegruppen (gute, intermediäre und schlechte Prognosegruppe) unterscheidet. Ihre Behandlung gehört zur Erfolgsgeschichte der Onkologie, denn selbst in fortgeschrittenen Tumorstadien sind hohe Heilungsraten möglich. Grundlage dieses Erfolges bildet vor Allem die cisplatinbasierte Chemotherapie. Abhängig von der Prognosegruppe werden drei bis vier Zyklen Chemotherapie appliziert. Dabei nimmt das Chemotherapie Schemata PEB die bedeutendste Rolle ein. Insbesondere bei Patienten der intermediären Prognosegruppe zielen derzeitige Therapiestrategien aktuell auf ein risikoadaptiertes Vorgehen, um die erreichten Behandlungserfolge bei gleichzeitiger Minimierung von Nebenwirkungen zu optimieren. Patienten der schlechten Prognosegruppe haben jedoch trotz Cisplatin-basierter Kombinationschemotherapie eine unbefriedigende Heilungschance. Innerhalb dieser Prognosegruppe konnten in den vergangenen Jahren mehrere Ausnahmepopulationen identifiziert werden, die von einer Therapieintensivierung profitieren könnten.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Am Soc Clin Oncol 15(2):594–603. https://doi.org/10.1200/JCO.1997.15.2.594. PMID: 9053482

  • Bajorin DF, Sarosdy MF, Pfister DG, Mazumdar M, Motzer RJ, Scher HI et al (1993) Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol Off J Am Soc Clin Oncol 11(4):598–606

    Article  CAS  Google Scholar 

  • Bokemeyer C, Köhrmann O, Tischler J, Weissbach L, Räth U, Haupt A et al (1996) A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with „good-risk“ metastatic non-seminomatous germ cell tumors. Ann Oncol Off J Eur Soc Med Oncol 7(10):1015–1021

    Article  CAS  Google Scholar 

  • Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B et al (1999) First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: a multivariate and matched-pair analysis. J Clin Oncol Off J Am Soc Clin Oncol 17(11):3450–3456

    Article  CAS  Google Scholar 

  • Bokemeyer C, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J et al (2001) Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer 91(7):1394–1401

    Article  CAS  PubMed  Google Scholar 

  • Bokemeyer C, Nichols CR, Droz J-P, Schmoll H-J, Horwich A, Gerl A et al (2002) Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol Off J Am Soc Clin Oncol 20(7):1864–1873

    Article  Google Scholar 

  • Bokemeyer C, Schleucher N, Metzner B, Thomas M, Rick O, Schmoll H-J et al (2003) First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer 89(1):29–35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bokemeyer C, Kollmannsberger C, Stenning S, Hartmann JT, Horwich A, Clemm C et al (2004) Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. Br J Cancer 91(4):683–687

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Golbey RB et al (1988) A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol Off J Am Soc Clin Oncol 6(8):1231–1238

    Article  CAS  Google Scholar 

  • Cary C, Jacob JM, Albany C, Masterson TA, Hanna NH, Einhorn LH et al (2018) Long-term survival of good-risk germ cell tumor patients after postchemotherapy retroperitoneal lymph node dissection: a comparison of BEP × 3 vs. EP × 4 and treating institution. Clin Genitourin Cancer 16(2):e307–e313

    Article  PubMed  Google Scholar 

  • Christian JA, Huddart RA, Norman A, Mason M, Fossa S, Aass N et al (2003) Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors. J Clin Oncol Off J Am Soc Clin Oncol 21(5):871–877

    Article  CAS  Google Scholar 

  • Clemm C, Bokemeyer C, Gerl A, Holzel D, Weissbach L, Bamberg M et al (2000) Randomized trial comparing cisplatin/etoposide/ifosfamide with carboplatin monochemotherapy in patients with advanced metastatic seminoma. Proc Am Soc Clin Oncol 19:326a. (abstr. 1283)

    Google Scholar 

  • Collette L, Sylvester RJ, Stenning SP, Fossa SD, Mead GM, de Wit R et al (1999) Impact of the treating institution on survival of patients with „poor-prognosis“ metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. J Natl Cancer Inst 91(10):839–846

    Article  CAS  PubMed  Google Scholar 

  • Collins DH, Pugh RC (1964) Classification and frequency of testicular tumours. Br J Urol 36(Suppl):1–11

    Google Scholar 

  • Cost GC, Caldwell BT, Adibi M, Raj GV, Sagalowsky AI, Margulis V (2016) Do Referral Patterns in Adolescents and Young Adults with Testicular Cancer Impact Oncologic Outcomes? J Adolesc Young Adult Oncol 5(3):248–53. https://doi.org/10.1089/jayao.2015.0057. Epub 2016 Feb 12

  • Culine S, Kerbrat P, Kramar A, Théodore C, Chevreau C, Geoffrois L et al (2007) Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP). Ann Oncol Off J Eur Soc Med Oncol 18(5):917–924

    Article  CAS  Google Scholar 

  • Culine S, Kramar A, Théodore C, Geoffrois L, Chevreau C, Biron P et al (2008) Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol Off J Am Soc Clin Oncol 26(3):421–427

    Article  CAS  Google Scholar 

  • Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H et al (2011) A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 22(5):1054–1061

    Article  CAS  PubMed  Google Scholar 

  • Doyle DM, Einhorn LH (2008) Delayed effects of whole brain radiotherapy in germ cell tumor patients with central nervous system metastases. Int J Radiat Oncol Biol Phys 70(5):1361–1364

    Article  PubMed  Google Scholar 

  • Droz J-P, Kramar A, Biron P, Pico J-L, Kerbrat P, Pény J et al (2007) Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol 51(3):739–746, discussion 747–748

    Article  CAS  PubMed  Google Scholar 

  • Feldman DR, Lorch A, Kramar A, Albany C, Einhorn LH, Giannatempo P et al (2016) Brain metastases in patients with germ cell tumors: prognostic factors and treatment options – an analysis from the Global Germ Cell Cancer Group. J Clin Oncol Off J Am Soc Clin Oncol 34(4):345–351

    Article  Google Scholar 

  • Fizazi K, Culine S, Kramar A, Amato RJ, Bouzy J, Chen I et al (2004) Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol Off J Am Soc Clin Oncol 22(19):3868–3876

    Article  Google Scholar 

  • Fizazi K, Pagliaro L, Laplanche A, Fléchon A, Mardiak J, Geoffrois L et al (2014) Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 15(13):1442–1450

    Article  CAS  PubMed  Google Scholar 

  • Fosså SD, de Wit R, Roberts JT, Wilkinson PM, de Mulder PHM, Mead GM et al (2003) Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). J Clin Oncol Off J Am Soc Clin Oncol 21(6):1107–1118

    Article  Google Scholar 

  • Friedman NB (1987) The function of the primordial germ cell in extragonadal tissues. Int J Androl 10(1):43–49

    Article  CAS  PubMed  Google Scholar 

  • Grimison PS, Stockler MR, Thomson DB, Olver IN, Harvey VJ, Gebski VJ et al (2010) Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst 102(16):1253–1262

    Article  CAS  PubMed  Google Scholar 

  • Hahn TL, Jacobson L, Einhorn LH, Foster R, Goulet RJ (1999) Hepatic resection of metastatic testicular carcinoma: a further update. Ann Surg Oncol 6(7):640–644

    Article  CAS  PubMed  Google Scholar 

  • Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD et al (2000) The relative risk of second nongerminal malignancies in patients with extragonadal germ cell tumors. Cancer 88(11):2629–2635

    Article  CAS  PubMed  Google Scholar 

  • Hartmann JT, Einhorn L, Nichols CR, Droz JP, Horwich A, Gerl A et al (2001) Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol Off J Am Soc Clin Oncol 19(6):1641–1648

    Article  CAS  Google Scholar 

  • Hartmann JT, Nichols CR, Droz J-P, Horwich A, Gerl A, Fossa SD et al (2002) Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol Off J Eur Soc Med Oncol 13(7):1017–1028

    Article  CAS  Google Scholar 

  • Hartmann JT, Rick O, Oechsle K, Kuczyk M, Gauler T, Schöffski P et al (2005) Role of postchemotherapy surgery in the management of patients with liver metastases from germ cell tumors. Ann Surg 242(2):260–266

    Article  PubMed  PubMed Central  Google Scholar 

  • Hinton S, Catalano PJ, Einhorn LH, Nichols CR, David Crawford E, Vogelzang N et al (2003) Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial. Cancer 97(8):1869–1875

    Article  CAS  PubMed  Google Scholar 

  • Horwich A, Dearnaley DP, A’Hern R, Mason M, Thomas G, Jay G, et al (1990/1992) The activity of single-agent carboplatin in advanced seminoma. Eur J Cancer Oxf Engl 28A(8–9):1307–1310

    Google Scholar 

  • Horwich A, Sleijfer DT, Fosså SD, Kaye SB, Oliver RT, Cullen MH et al (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol Off J Am Soc Clin Oncol 15(5):1844–1852

    Article  CAS  Google Scholar 

  • Kaye SB, Mead GM, Fossa S, Cullen M, de Wit R, Bodrogi I et al (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol Off J Am Soc Clin Oncol 16(2):692–701

    Article  CAS  Google Scholar 

  • Kier MG, Lauritsen J, Mortensen MS, Bandak M, Andersen KK, Hansen MK et al (2017) Prognostic factors and treatment results after bleomycin, etoposide, and cisplatin in germ cell cancer: a population-based study. Eur Urol 71(2):290–298

    Article  CAS  PubMed  Google Scholar 

  • Kollmannsberger C, Nichols C, Bamberg M, Hartmann JT, Schleucher N, Beyer J et al (2000) First-line high-dose chemotherapy +/− radiation therapy in patients with metastatic germ-cell cancer and brain metastases. Ann Oncol Off J Eur Soc Med Oncol 11(5):553–559

    Article  CAS  Google Scholar 

  • Kundu SD, Feldman DR, Carver BS, Gupta A, Bosl GJ, Motzer RJ et al (2015) Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. J Urol 193(2):513–518

    Article  PubMed  Google Scholar 

  • Lauritsen J, Kier MGG, Bandak M, Mortensen MS, Thomsen FB, Mortensen J et al (2016) Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin. J Clin Oncol Off J Am Soc Clin Oncol 34(13):1492–1499

    Article  CAS  Google Scholar 

  • Loehrer PJ, Johnson D, Elson P, Einhorn LH, Trump D (1995) Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol Off J Am Soc Clin Oncol 13(2):470–476

    Article  Google Scholar 

  • Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. J Clin Oncol Off J Am Soc Clin Oncol 19(9):2534–2541

    Article  CAS  Google Scholar 

  • Mead GM, Stenning SP (1997) The international germ cell consensus classification: a new prognostic factor-based staging classification for metastatic germ cell tumours. Clin Oncol R Coll Radiol G B 9(4):207–209

    Article  CAS  Google Scholar 

  • Mencel PJ, Motzer RJ, Mazumdar M, Vlamis V, Bajorin DF, Bosl GJ (1994) Advanced seminoma: treatment results, survival, and prognostic factors in 142 patients. J Clin Oncol Off J Am Soc Clin Oncol 12(1):120–126

    Article  CAS  Google Scholar 

  • Motzer RJ, Nichols CJ, Margolin KA, Bacik J, Richardson PG, Vogelzang NJ et al (2007) Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25(3):247–256

    Article  CAS  PubMed  Google Scholar 

  • Necchi A, Mariani L, Di Nicola M, Lo Vullo S, Nicolai N, Giannatempo P et al (2015) High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. Ann Oncol Off J Eur Soc Med Oncol 26(1):167–172

    Article  CAS  Google Scholar 

  • Necchi A, Pond GR, Nicolai N, Giannatempo P, Raggi D, Adra N et al (2017) A suggested prognostic reclassification of intermediate and poor-risk nonseminomatous germ cell tumors. Clin Genitourin Cancer 15(2):306–312.e3

    Article  PubMed  Google Scholar 

  • Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G (1990) Hematologic neoplasia associated with primary mediastinal germ-cell tumors. N Engl J Med 322(20):1425–1429

    Article  CAS  PubMed  Google Scholar 

  • Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J et al (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol Off J Am Soc Clin Oncol 9(7):1163–1172

    Article  CAS  Google Scholar 

  • Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ (1998) Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol Off J Am Soc Clin Oncol 16(4):1287–1293

    Article  CAS  Google Scholar 

  • Nini A, Konieczny M, Winter C, Lusch A, Krauspe R, Albers P (2018) Surgical management and outcomes of patients with bone metastases in germ cell tumors: A case series. Urol Oncol 36(2):82.e1–82.e5

    Article  Google Scholar 

  • O’Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A (2003) Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol Off J Eur Soc Med Oncol 14(1):91–96

    Article  Google Scholar 

  • Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger LA, Oing C et al (2012) Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol 138(6):947–952

    Article  CAS  PubMed  Google Scholar 

  • Oing C, Oechsle K, Necchi A, Loriot Y, De Giorgi U, Fléchon A et al (2017) Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study. Ann Oncol Off J Eur Soc Med Oncol 28(3):576–582

    Article  CAS  Google Scholar 

  • Ozols RF, Ihde DC, Linehan WM, Jacob J, Ostchega Y, Young RC (1988) A randomized trial of standard chemotherapy v a high-dose chemotherapy regimen in the treatment of poor prognosis nonseminomatous germ-cell tumors. J Clin Oncol Off J Am Soc Clin Oncol 6(6):1031–1040

    Article  CAS  Google Scholar 

  • Pietzak EJ, Assel M, Becerra MF, Tennenbaum D, Feldman DR, Bajorin DF, et al (2018) Histologic and oncologic outcomes following liver mass resection with retroperitoneal lymph node dissection in patients with nonseminomatous germ cell tumor. Urology 118:114–118. https://doi.org/10.1016/j.urology.2018.04.009. Epub 2018 Apr 25

  • Rivoire M, Elias D, De Cian F, Kaemmerlen P, Théodore C, Droz JP (2001) Multimodality treatment of patients with liver metastases from germ cell tumors: the role of surgery. Cancer 92(3):578–587

    Article  CAS  PubMed  Google Scholar 

  • Saxman SB, Finch D, Gonin R, Einhorn LH (1998) Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience. J Clin Oncol Off J Am Soc Clin Oncol 16(2):702–706

    Article  CAS  Google Scholar 

  • Schmoll HJ, Harstrick A, Bokemeyer C, Dieckmann KP, Clemm C, Berdel WE et al (1993) Single-agent carboplatinum for advanced seminoma. A phase II study. Cancer 72(1):237–243

    Article  CAS  PubMed  Google Scholar 

  • Schmoll H-J, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schöffski P et al (2003) Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol Off J Am Soc Clin Oncol 21(22):4083–4091

    Article  CAS  Google Scholar 

  • Schrader M, Weissbach L, Hartmann M, Krege S, Albers P, Miller K et al (2010) Burden or relief: do second-opinion centers influence the quality of care delivered to patients with testicular germ cell cancer? Eur Urol 57(5):867–872

    Article  PubMed  Google Scholar 

  • Schrader M, Zengerling F, Hakenberg OW, Protzel C (2016) German national second-opinion network for testicular cancer and penile carcinoma : two sources for evidence-based information. Urol Ausg A 55(9):1192–1198

    Article  CAS  Google Scholar 

  • Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn Cedermark G, Ståhl O, et al (1990/2018) Intermediate prognosis in metastatic germ cell tumours-outcome and prognostic factors. Eur J Cancer Oxf Engl 94:16–25

    Google Scholar 

  • Shamash J, Sarker S-J, Huddart R, Harland S, Joffe JK, Mazhar D et al (2017) A randomized phase III study of 72 h infusional versus bolus bleomycin in BEP (bleomycin, etoposide and cisplatin) chemotherapy to treat IGCCCG good prognosis metastatic germ cell tumours (TE-3). Ann Oncol Off J Eur Soc Med Oncol 28(6):1333–1338

    Article  CAS  Google Scholar 

  • Toner GC, Geller NL, Tan C, Nisselbaum J, Bosl GJ (1990) Serum tumor marker half-life during chemotherapy allows early prediction of complete response and survival in nonseminomatous germ cell tumors. Cancer Res 50(18):5904–5910

    CAS  PubMed  Google Scholar 

  • Toner GC, Stockler MR, Boyer MJ, Jones M, Thomson DB, Harvey VJ et al (2001) Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group. Lancet 357(9258):739–745

    Article  CAS  PubMed  Google Scholar 

  • Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316(23):1435–1440

    Article  CAS  PubMed  Google Scholar 

  • Wit R de (2007) Refining the optimal chemotherapy regimen in good prognosis germ cell cancer: interpretation of the current body of knowledge. J Clin Oncol Off J Am Soc Clin Oncol 25(28):4346–4349

    Google Scholar 

  • Wit R de, Stoter G, Sleijfer DT, Kaye SB, de Mulder PH, ten Bokkel Huinink WW et al (1995) Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 71(6):1311–1314

    Google Scholar 

  • Wit R de, Stoter G, Kaye SB, Sleijfer DT, Jones WG, ten Bokkel Huinink WW et al (1997) Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol Off J Am Soc Clin Oncol 15(5):1837–1843

    Google Scholar 

  • Wit R de, Stoter G, Sleijfer DT, Neijt JP, ten Bokkel Huinink WW, de Prijck L et al (1998) Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 78(6):828–832

    Google Scholar 

  • Wit R de, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD et al (2001) Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol Off J Am Soc Clin Oncol 19(6):1629–1640

    Google Scholar 

  • Wit R de, Skoneczna I, Daugaard G, De Santis M, Garin A, Aass N et al (2012) Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol Off J Am Soc Clin Oncol 30(8):792–799

    Google Scholar 

  • Wozniak AJ, Samson MK, Shah NT, Crawford ED, Ford CD, Altman SJ et al (1991) A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study. J Clin Oncol Off J Am Soc Clin Oncol 9(1):70–76

    Article  CAS  Google Scholar 

  • Xiao H, Mazumdar M, Bajorin DF, Sarosdy M, Vlamis V, Spicer J et al (1997) Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol Off J Am Soc Clin Oncol 15(7):2553–2558

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes und Universität des Saarlandes, Homburg/Saar, Deutschland

    Julia Heinzelbecker

  2. Praxis und Tagesklinik, Friedrichshafen, Deutschland

    Frank Mayer

  3. Klinik für Hämatologie, Onkologie und Immunologie, Franziskus Hospital, Bielefeld, Deutschland

    Jörg T. Hartmann

Authors
  1. Julia Heinzelbecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jörg T. Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jörg T. Hartmann .

Editor information

Editors and Affiliations

  1. Helios Marien Klinikum Duisburg, Duisburg, Nordrhein-Westfalen, Deutschland

    Herbert Rübben

  2. Caritaskrankenhaus St. Josef, Regensburg, Deutschland

    Maximilian Burger

  3. Klinik und Poliklinik für Urologie, Universitätsklinikum Jena, Jena, Thüringen, Deutschland

    Marc-Oliver Grimm

  4. Urologische Klinik/Poliklinik, Universitätsklinikum Rostock, Rostock, Mecklenburg-Vorpommern, Deutschland

    Oliver Hakenberg

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Heinzelbecker, J., Mayer, F., Hartmann, J.T. (2021). Fortgeschrittene Hodentumoren: Therapie. In: Rübben, H., Burger, M., Grimm, MO., Hakenberg, O. (eds) Uroonkologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-54652-9_69-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-54652-9_69-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-54652-9

  • Online ISBN: 978-3-662-54652-9

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation